 placebo treatment ecuadorian cutan leishmaniasi pentaval antimoni standard treatment leishmaniasi administr agent allopurinol ribonucleosid subject sever clinic trial studi agent patient ecuadorian cutan leishmaniasi patient treatment group mean reduct lesion size patient pentostam mg sb/kg/day day week wide rang individu valu lesion first week therapi lesion re-epitheli post-treat followup pentostam patient degre lesion resolut initi heal rate patient evid relaps month complet heal rate month observ period patient untreat control group high rate patient re-epitheli lesion month observ initi heal rate mean reduct lesion size untreat patient week patient allopurinol ribonucleosid qid probenecid qid day lesion patient time month followup rate